Skip to main content
Literatur
1.
Zurück zum Zitat Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, Nicholson AG, Groome P, Mitchell A, Bolejack V, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11(1):39–51CrossRefPubMed Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE, Nicholson AG, Groome P, Mitchell A, Bolejack V, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11(1):39–51CrossRefPubMed
2.
Zurück zum Zitat Zelen M (1973) Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 4(2):31–42 Zelen M (1973) Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 4(2):31–42
4.
Zurück zum Zitat Fox W, Scadding JG (1973) Medical Research Counsil comparativ trial of surgery and radiotherapy for primary treatment of small celled or oat celled carcinoma of the bronchus. Lancet 302:57–60CrossRef Fox W, Scadding JG (1973) Medical Research Counsil comparativ trial of surgery and radiotherapy for primary treatment of small celled or oat celled carcinoma of the bronchus. Lancet 302:57–60CrossRef
5.
Zurück zum Zitat Lad T, Piantadosi S, Thomas P et al (1994) A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 106:320S–323SCrossRefPubMed Lad T, Piantadosi S, Thomas P et al (1994) A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 106:320S–323SCrossRefPubMed
6.
Zurück zum Zitat Mascaux C, Paesmans M, Berghmans T et al (2000) A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30:23–36CrossRefPubMed Mascaux C, Paesmans M, Berghmans T et al (2000) A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer 30:23–36CrossRefPubMed
7.
Zurück zum Zitat Takada BM, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer : results of the Japan Clinical Oncology Group study 9104. J Clin Oncol 20(14):3054–3060. https://doi.org/10.1200/JCO.2002.12.071 CrossRefPubMed Takada BM, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer : results of the Japan Clinical Oncology Group study 9104. J Clin Oncol 20(14):3054–3060. https://​doi.​org/​10.​1200/​JCO.​2002.​12.​071 CrossRefPubMed
8.
Zurück zum Zitat Murray BN, Coy P, Pater JL et al (1993) Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 11(2):336–344CrossRefPubMed Murray BN, Coy P, Pater JL et al (1993) Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol 11(2):336–344CrossRefPubMed
9.
Zurück zum Zitat Spiro SG, James LE, Rudd RM et al (2006) Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer : a London lung cancer group multicenter randomized clinical trial and meta-analysis. J Clin Oncol 24:3823-3830CrossRefPubMed Spiro SG, James LE, Rudd RM et al (2006) Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer : a London lung cancer group multicenter randomized clinical trial and meta-analysis. J Clin Oncol 24:3823-3830CrossRefPubMed
11.
Zurück zum Zitat Turrisi AT III, Kim K, Blum R et al (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265–271CrossRefPubMed Turrisi AT III, Kim K, Blum R et al (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265–271CrossRefPubMed
12.
Zurück zum Zitat Schild S, Bonner J, Shanahan TG et al (2004) Long tern results of a phase III trial comparing once daily radiotherapy with twice daily radiotherapy in limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 59:943–951CrossRefPubMed Schild S, Bonner J, Shanahan TG et al (2004) Long tern results of a phase III trial comparing once daily radiotherapy with twice daily radiotherapy in limited stage small cell lung cancer. Int J Radiat Oncol Biol Phys 59:943–951CrossRefPubMed
13.
Zurück zum Zitat Faivre-Finn C et al (2016) CONVERT: An international randomised trial of concurrent chemoradiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS). ASCO 2016. The University of Manchester, Institute of Cancer Sciences, Manchester, Abs. 8504 Faivre-Finn C et al (2016) CONVERT: An international randomised trial of concurrent chemoradiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS). ASCO 2016. The University of Manchester, Institute of Cancer Sciences, Manchester, Abs. 8504
14.
Zurück zum Zitat Auperin A, Arriagada R, Pignon JP et al (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341:476–484CrossRefPubMed Auperin A, Arriagada R, Pignon JP et al (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341:476–484CrossRefPubMed
15.
Zurück zum Zitat Le Péchoux C, Sun A, Slotman BJ, De Ruysscher D, Belderbos J, Gore EM (2009) Prophylactic cranial irradiation for patients with lung cancer. Lancet Oncol 10:467-474CrossRefPubMed Le Péchoux C, Sun A, Slotman BJ, De Ruysscher D, Belderbos J, Gore EM (2009) Prophylactic cranial irradiation for patients with lung cancer. Lancet Oncol 10:467-474CrossRefPubMed
16.
Zurück zum Zitat Niell HB, Herndon JE, Miller AA et al (2005) Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: cancer and leukemia group B trial 9732. J Clin Oncol 23:3752–3759CrossRefPubMed Niell HB, Herndon JE, Miller AA et al (2005) Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: cancer and leukemia group B trial 9732. J Clin Oncol 23:3752–3759CrossRefPubMed
17.
Zurück zum Zitat Reck M, von Pawel J, Macha HN et al (2003) Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 95:1118–1127CrossRefPubMed Reck M, von Pawel J, Macha HN et al (2003) Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 95:1118–1127CrossRefPubMed
18.
Zurück zum Zitat Lara PN, Natale R, Crowley J et al (2009) Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive stage small cell lung cancer. J Clin Oncol 27:2530–2535CrossRefPubMedPubMedCentral Lara PN, Natale R, Crowley J et al (2009) Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive stage small cell lung cancer. J Clin Oncol 27:2530–2535CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Hanna N, Bunn PA Jr., Langer C et al (2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24:2038–2043CrossRefPubMed Hanna N, Bunn PA Jr., Langer C et al (2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24:2038–2043CrossRefPubMed
20.
Zurück zum Zitat Schmittel A, Sebastian M, Fischer von Weikersthal L et al (2011) A German multicenter randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first line therapy for extensive disease small cell lung cancer. Ann Oncol 22:1796–1804CrossRef Schmittel A, Sebastian M, Fischer von Weikersthal L et al (2011) A German multicenter randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first line therapy for extensive disease small cell lung cancer. Ann Oncol 22:1796–1804CrossRef
21.
Zurück zum Zitat Eckardt JR, von Pawel J, Papai Z et al (2006) Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 24:2044–2051CrossRefPubMed Eckardt JR, von Pawel J, Papai Z et al (2006) Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 24:2044–2051CrossRefPubMed
23.
Zurück zum Zitat Lee SM, James LE, Qian W et al (2009) Comparison of Gecitabine and carboplatin versus cisplatin and etoposide for patients with poo prognosis small cell lung cancer. Thorax 64:75–80CrossRefPubMed Lee SM, James LE, Qian W et al (2009) Comparison of Gecitabine and carboplatin versus cisplatin and etoposide for patients with poo prognosis small cell lung cancer. Thorax 64:75–80CrossRefPubMed
24.
Zurück zum Zitat Socinski M, Smit E, Lorigan P et al (2009) Phase III Study of pemetrexed plus carboplatin compared with etoposide plus caraboplatin in chemotherapy naïve patients with extensive small cell lung cancer. J Clin Oncol 27:4787–4792CrossRefPubMed Socinski M, Smit E, Lorigan P et al (2009) Phase III Study of pemetrexed plus carboplatin compared with etoposide plus caraboplatin in chemotherapy naïve patients with extensive small cell lung cancer. J Clin Oncol 27:4787–4792CrossRefPubMed
25.
Zurück zum Zitat Satouchi M, Kotani Y, Shibata T et al (2014) Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive disease small cell lung cancer. J Clin Oncol 32:1262–1268CrossRefPubMed Satouchi M, Kotani Y, Shibata T et al (2014) Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive disease small cell lung cancer. J Clin Oncol 32:1262–1268CrossRefPubMed
27.
Zurück zum Zitat Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus P, Collette L, Musat E, Senan S (2007) EORTC Radiation Oncology Group and Lung Cancer Group: prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357(7):664–672CrossRefPubMed Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M, Postmus P, Collette L, Musat E, Senan S (2007) EORTC Radiation Oncology Group and Lung Cancer Group: prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357(7):664–672CrossRefPubMed
29.
Zurück zum Zitat O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24(34):5441–5447CrossRefPubMed O’Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cuceviá B, Juhasz G, Thatcher N, Ross GA, Dane GC, Crofts T (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24(34):5441–5447CrossRefPubMed
30.
Zurück zum Zitat von Pawel J, Schiller JH, Shepherd FA et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658–667CrossRef von Pawel J, Schiller JH, Shepherd FA et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17:658–667CrossRef
31.
Zurück zum Zitat von Pawel J, Jotte R, Spigel DR, O’Brien ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Schütte W, Lorigan P, Reck M, Domine M, Shepherd FA, Li S, Renschler MF (2014) Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 32(35):4012–4019. https://doi.org/10.1200/JCO.2013.54.5392 CrossRef von Pawel J, Jotte R, Spigel DR, O’Brien ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Schütte W, Lorigan P, Reck M, Domine M, Shepherd FA, Li S, Renschler MF (2014) Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol 32(35):4012–4019. https://​doi.​org/​10.​1200/​JCO.​2013.​54.​5392 CrossRef
32.
33.
Zurück zum Zitat Allen JW, Moon J, Redman M et al (2014) Southwest Oncology GRoup S0802:a randomized phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum treated small cell lung cancer. J Clin Oncol 32:2463-2470CrossRefPubMedPubMedCentral Allen JW, Moon J, Redman M et al (2014) Southwest Oncology GRoup S0802:a randomized phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum treated small cell lung cancer. J Clin Oncol 32:2463-2470CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Goto K, Ohe Y, Shibata T et al (2016) Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 17(8):1147–1157. https://doi.org/10.1016/S1470-2045(16)30104-8 CrossRefPubMed Goto K, Ohe Y, Shibata T et al (2016) Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 17(8):1147–1157. https://​doi.​org/​10.​1016/​S1470-2045(16)30104-8 CrossRefPubMed
Metadaten
Titel
Therapie des kleinzelligen Bronchialkarzinoms
verfasst von
Prof. Dr. Martin Wolf
Publikationsdatum
09.03.2018
Verlag
Springer Medizin
Erschienen in
best practice onkologie / Ausgabe 2/2018
Print ISSN: 0946-4565
Elektronische ISSN: 1862-8559
DOI
https://doi.org/10.1007/s11654-018-0069-7

Weitere Artikel der Ausgabe 2/2018

best practice onkologie 2/2018 Zur Ausgabe

Onko aktuell

Onko aktuell

Was Patienten fragen

Was Patienten fragen